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Context: The extra-intestinal manifestations of inflammatory bowel disease (IBD) are 
common and involve other organs or systems for example; urinary system. 
Evidence Acquisitions: For this review, we used a variety of sources by searching through Web 
of Science, PubMed, EMBASE, Scopus and directory of open access journals (DOAJ).
Results: Urinary complications may occur in up to 22% of patients and nephrolithiasis 
or renal/kidney stones have been suggested to be a common manifestation of disease in 
forms of uric acid, calcium phosphate or calcium oxalate. We performed a meta-analysis 
on five clinical trials and reported that correlation between IBD and formation of stone in 
renal system is positive and significant (Fix-effect model; CI: 95%, P <0.001, and random-
effect model; CI: 95%, P = 0.03).
Conclusions: Based on the reports of the clinical trials, calcium oxalate is more prevalent in 
Crohn’s disease (CD) than in ulcerative colitis (UC).
ABSTRACT
Implication for health policy/practice/research/medical education:
In patients with IBD, ureteral obstruction, enterovesical fistulas, and urinary tract stones have the most prevalence. Ureteral 
obstruction, enterovesical fistulas are directly related to disease process but urinary tract stones are indirectly. Extra-intestinal 
urolithiasis symptoms can particularly be found in the patients with Crohn’s disease compared with UC which might be in 
result of  steroid dependency and/or ileal involvement of  CD patients. Based on the reports of  the clinical trials, calcium 
oxalate is more prevalent in Crohn’s disease than in UC.
Please cite this paper as: Ganji-Arjenaki M, Nasri H, Rafieian-Kopaei M. Nephrolithiasis as a common urinary system manifestation 
of  inflammatory bowel diseases; a clinical review and meta-analysis. J Nephropathol. 2017;6(3):264-269. DOI: 10.15171/
jnp.2017.42.
1. Background
Inflammatory bowel diseases (IBDs) are associated 
with extra-intestinal manifestations such as muscu-
loskeletal, dermatologic, ophthalmologic, hematolog-
ic, cardiovascular, pulmonary, neurologic, pancreatic, 
hepatobiliary and genitourinary involvement. Crohn’s 
disease (CD) and ulcerative colitis (UC) are the main 
forms of  IBD that differently affect the frequent rate 
of  extra-intestinal complications (1). 
Pathogenic factors of  extra-intestinal manifestations 
remain unclear. Some organ disorders may be linked 
to immunologic origins, following intestinal bacterial 
overgrowth or side effects of  therapy used to control 
bowel inflammation. In overall, pathogenesis of  IBD 
is various including genetics, immunology responses 
or environmental factors (2,3).
Urinary complications in IBD patients have been 
reported in up to 22% of  subjects that ureteral 
obstruction, enterovesical fistulas and kidney stones 
are the most common manifestations (2). Urinary 
tract complications including ileal masses or abscesses 
that may result in ureteric obstruction or fistulas to 
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the bladder or urethra are the most widespread in CD 
compared with UC patients (4). 
In a clinical trial 312 CD patients who were considered 
from urinary tract complications viewpoints, 77 
(24.7%) had urologic symptoms, 51 (16%) influenced 
by simple cystitis and the subjects which acquired 
structural urinary tract abnormalities had most 
common manifestations (5,6). 
This review article tries to discuss the relations of 
these parameters other renal manifestations of  IBD, 
and also tries to find out the relation between IBD and 
urinary system stones. We reviewed and performed 
a meta-analysis on five studies of  clinical trials that 
assessed the occurrence of  renal stones in patients 
with IBD. 
Materials and Methods
For this review, we used a variety of  sources by searching 
through Web of  Science, PubMed, EMBASE, Scopus 
and directory of  open access journals (DOAJ). The 
search was performed using combinations of  the 
following key words and or their equivalents such as; 
Crohn’s disease, nephrolithiasis, inflammatory bowel 
disease, ulcerative colitis and kidney stone.
Results
The relation between IBD and renal or urologic 
complications is presented in Table 1. As can be seen 
the complications are related to the disease process or 
might be iatrogenic which are discussed in more detail 
below.
Entero-urinary fistulas
The prevalence of  entero-urinary fistulas in patients 
of  CD is 24-32% (1). After diverticulitis and cancer, 
CD is estimated to be the third cause of  entero-
vesical fistulas (EVF) with calculating 5%-17%, first 
cause of  ileovesical fistulas and EVF in patients 
higher than 40 years with accounting for more than 
75% but in patients >50 years old accounts for 
1.8%. EVF can cause pneumaturia and fecaluria with 
frequencies of  38%–94% and 17%–63%, respectively, 
and epididymitis, hematuria, urinary tract infections, 
prostatitis, fever, abdominal pain and involuntary 
urine passage or urorrhea (7-13).
Management options for EVF are surgery and 
intervention of  medications. Antibiotics and anti-
inflammatory medications such as aminosalicylates and 
corticosteroids or cyclosporine and 6-mercaptopurine 
have been used successfully (14-18).
Ureteral obstruction
In 50% to 73% of  patients having CD and in more than 
Table 1. Renal complications of  patient in inflammatory bowel 
disease
Complications directly related to disease process
Enterourinary fistulas
Ureteral obstruction
Genital involvement
Complications indirectly related to disease process
Nephrolithiasis
Glomerulonephritis
Amyloidosis
Iatrogenic complications
Medications
Aminosalicylates
Cyclosporine
50% of  patients having UC, the obstruction ureteral 
is not usually occurred by stones (5). Non-calculous 
obstruction (NCO) in CD is due to retroperitoneal 
inflammation or an EVF near the ureter and surgery 
is the treatment choice (19).
Genital involvement
Genital involvement in IBD is uncommon and is 
associated with and erythema, edema, ulceration, 
fibrosis of  vulva, scrotum penis from direct extension 
of  underlying disease, pyoderma gangrenosum, or 
abscesses, phimosis, balanoposthitis, metastatic CD 
or granulomatous inflammation in seminal vesicles, 
prostate gland, and scrotum. Genital involvement 
may result in perineal pain, urethral strictures, urethral 
discharge, fever, and might parallel the activity of 
underlying IBD. The treatment options for this include 
antibiotics, systemic steroids, immunosuppression, 
resection of  involved bowel, skin and circumcision 
(20-25).
Nephrolithiasis
The nephrolithiasis prevalence in IBD patients has 
been suggested to be more than general, in adults the 
prevalence is more than children and in CD patients is 
higher compared with UC patients and in CD patients 
who have extensive surgery is the highest (26-28).
Multiple kidney stones are occurred in IBD and in CD 
the stones are occurred often in the right ureter and 
terminal ileum (7%–15%) (5,29). The stones are usually 
composed of  calcium oxalate that result in high urinary 
oxalate, calcium phosphate that result in increased Ca 
mobilization from bone, decreased tubular resorption 
of  Ca and uric acid that result in decreased urate 
solubility in an acidic, concentrated urine. On the other 
hand, low levels of  citrate, magnesium, anti-lithogenic 
agents, accompanying bile salt and fat malabsorption 
cause stone development (30).
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The risk of  calcium oxalate stone is increased in 
patients having an intact colon, due to high absorption 
of  sodium-bound oxalate in colon, but in patients with 
an ileostomy, uric acid stones are increased because of 
frequent dehydration (31).
Despite existence of  hyperoxaluria, hypocitraturia, 
hypomagnesuria, hypophosphaturia, low urinary pH 
and low urine volume in patients with IBD, but most 
of  them have not renal stones (32), probably due to 
attention to individual genetic.
Glomerulonephritis
The occurrence of  glomerulonephritis in CD and 
UC has been reported (33, 34). The occurrence 
of  glomerulonephritis is not association with 
duration of  disease, but has correlation with level 
of  inflammation in bowel and bile duct (35-37). For 
improving the renal function in patients having  IBD 
with glomerulonephritis, the use of  steroids is helpful 
(38,39).
Amyloidosis
Moschkowitz in 1936 reported the association 
between secondary amyloidosis (A) and IBD for the 
first time (40). It has been shown in clinical studies that 
amyloidosis is occurred in about 1% of  IBD patients. 
Amyloidosis is 3-fold in male subjects compared with 
female ones. In CD patients the prevalence is 10-fold 
compared with UC patients and it correlates with 
extra-intestinal complications (36,41-43).
The secondary amyloidosis pathogenesis has been 
attributed to serum amyloid-A (SAA), which is an 
acute phase protein with unknown function  (44) 
that expression level is increased in response to 
inflammation and may lead to amyloidosis. In patients 
with IBD amyloidosis may affect the kidney function 
and cause proteinuria followed by nephrotic syndrome 
and subsequently renal insufficiency (3,36,45,46). 
Finally, in CD with azathioprine and plasmapheresis, 
treatment of  renal amyloidosis may be useful (47,48).
Complications of  medical therapy
Drugs such as corticosteroids, azathioprine, 
6-mercaptopurine, metronidazole and low dose of 
methotrexate have little or no nephrotoxicity (49-54). 
Aminosalicylates and cyclosporine are the medications 
with potential renal toxicity.
Aminosalicylates (5-ASA)
Sulfasalazine (5-ASA bound to sulfapyridine), 
mesalamine, and olsalazine are types of  aminosalicylates 
that renal toxicities with these agents have been reported 
(55-58). These are associated with clinical improvement 
in active UC and are essential in maintaining remission. 
Mesalazine is arguable in CD and seems to be beneficial 
only in mild ileocolonic disease (59). Renal deficiency 
might occur in more than 1% of  patients using 5-ASA, 
but renal clinical disturbance may occur in only 1 to 500 
IBD patients (60).
Treatment with 5-ASA may cause renal toxicity that 
include glomerulonephritis, change in nephropathy 
with interstitial nephritis and nephrotic syndrome, 
which  in these cases might be associated with 
nephrogenic diabetes (61,62).
Cyclosporine
Dose of  cyclosporine (CsA) is related to nephrotoxicity 
(63,64). Cyclosporine has a role in tenacious UC, which 
by inhibiting calcineurin (a calmodulin and calcium 
dependent serine/threonine protein phosphatase)  can 
block the production of  interferon- γ and interleukin-2 
interrupting the cellular immune response (65,66).
Meta-analysis
We analyzed the data of  5 clinical trials by evaluating 
the rate difference with their 95% confidence 
intervals. Then, the results were reported in form of 
Fix and random effect- models and the presence of 
heterogeneity across trials by using the I2 statistical 
analysis. The analysis was performed by comprehensive 
meta-analysis V3 software. The results of  the studies 
are outlined in Table 2.
Analysis showed that correlation between IBD 
and renal stone is significant (Figure 1), with fix-
effect model; CI: 95%, P value < 0.001, I2: 88.52 and 
Random-effect model; CI:95%, P value = 0.03.
As it was said hyperoxaluria is a common extra 
intestinal complication of  IBD that might be result 
Table 2. Clinical trials studies considered in meta-analysis
Study name IBD number Non-IBD number Sex (F:M) CD number UC number
Nightingale et al (67) 38 46 57:27 32 6
McConnell et al (68) 40 17 24:16 25 15
Ishii et al (69) 39 59 22:76 39 0
Kumar et al (70) 48 48 21:27 11 37
Parks  et al (71) 133 1156 - - -
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from malabsorption and the absence of  intestinal 
oxalate degrading bacteria. Intestinal hyperoxaluria 
is a cause in formation of  oxalate stones in kidneys. 
Since probiotics in treatment of  IBD are efficacious, 
therefore some types of  probiotics should be useful 
in reduction of  renal stone in patients with IBD (72). 
Conclusion
In patients with IBD, ureteral obstruction, 
enterovesical fistulas, and urinary tract stones have the 
most prevalence. Ureteral obstruction, enterovesical 
fistulas are directly related to disease process but 
urinary tract stones are indirectly. Extra-intestinal 
urolithiasis symptoms can particularly be found 
in the patients with CD compared with UC which 
might be in result of  steroid dependency and/or ileal 
involvement of  CD patients. Clinical trial studies 
pointed that hyperoxaluria has mostly redundancy in 
CD that results in high urinary oxalate that would be 
associated with low pH and urine volume.
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